Last reviewed · How we verify

Adjunct to incisional glaucoma surgery — Treatment Landscape & Competitive Intelligence

Adjunct to incisional glaucoma surgery (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Adjunct to incisional glaucoma surgery, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Mitozytrex MITOMYCIN Kyowa Kirin Co., Ltd. Alkylating Drug [EPC] Indoleamine 2,3-dioxygenase 1 1981-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Kyowa Kirin Co., Ltd. · 1 drug in Adjunct to incisional glaucoma surgery

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Adjunct to incisional glaucoma surgery:

Cite this brief

Drug Landscape (2026). Adjunct to incisional glaucoma surgery — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/adjunct-to-incisional-glaucoma-surgery. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing